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ABSTRACT 
Highly active antiretroviral viral therapy (HAART), a combination of 
three antiretrovirals from at least two drug classes for optimization of 
hindrance to HIV replication has greatly increased life expectance. 
There however, exist numerous of these combinations and thus the 
questions of which is the best HAART combination with respect to the 
individual’s haematological status. To investigate this, blood samples 
were collected from 231 retropositive subjects on six different HAART 
combinations at least six months after HAART commencement, 
assayed for CD4 and some haematological parameters using cyflow 
and sysmex(KX-21)  autoanalysier. Baseline data was accessed from 
the LAMIS data base. The difference between baseline and values after 
HAART was taken and statistically compared. HAART evaluated  
includes, Combivir(NVP), Combivir(EFV), Truvada(NVP), Truvada(EFV), Lanten(NVP) 
and Lanten(EFV). The difference in the parameters assayed are: CD4(cellmm
-3
): 154, 205, 
172, 206, 262, and 230(P=0.478). Haemoglobin(gdl-1): -0.78, -0.73, 2.35, 1.48, 1.11 and 
1.27(P=0.010). PCV(%):  -2.34, -2.19, 7.65, 7.02, 3.36 and 3.12(P=0.0001). WBC(10
3
µl
-1
): -
1.19, -1.02, -0.37, 0.06, 1.14 and -0.63(P=0.001). Neutrophil(%): -1.51, -1.83, 3.87, 2.07, 
2.71, 2.71 and 1.97(P=0.868). Lymphocyte(%): -4.26, -2.87, -1.45, -0.19, 2.36 and 
3.40(P=0.790). Eosinophil(%): -0.41, 0.14, -2.65, 0.14, -0.46 and 0.12(P=0.094). 
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Platelet(10
3
µl
-1
): -49, -39, -53, -53, -47 and -35(P=0.931). The Zidovudine based 
combinations showed anaemic tendencies; Nevirapen based combinations showed 
Eosinopenic tendencies. All HAART used induced good immunologic responses along with 
thrombocytopenic tendencies. The data generated was however insufficient to discriminate 
one combination as being better than the other, rather it was observed that the haematological 
profile of clients must be well considered when selecting HAART. 
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1. INTRODUCTION 
Highly active retroviral therapy (HAART) is a cocktail consisting of at least three drugs 
belonging to at least two types or classes of antiretroviral agents. Typically, these classes are 
two nucleoside analogue reverse transcriptase inhibitors (NRTIs) plus either a protease 
inhibitor (PIs) or a non-nucleoside reverses transcriptase inhibitor (NNRTI).
[1, 2]
 Other classes 
of drugs such as entry inhibitors provide treatment options for patients who are infected with 
viruses already resistant to common therapies, although they are not widely available and not 
typically accessible in resource limited settings.
[1] 
 
HIV infection is characterized by a progressive damage of the body’s immune systemwhich 
in turn results in a number of opportunistic infection, immunological and haematological 
complications.
[3]
 The goal of HAART is however, firstly, to suppress HIV viral load in 
plasma to a level below detection and secondly to restore immune function as demonstrated 
by an increased number of CD4+ T-cells. This has greatly increased chances of long term 
survival as it leaves more drugs available to the patient for longer period of time.
[4]
 
 
Haematological complications have been documented to be the second most common cause 
of morbidity and mortality in HIV patients
[5, 6]
 and are generally marked with cytopoenias 
such as anaemia, neutropenia, lymphopenia and thrombocytopenia.
[7]
 The incidence and 
severity of the cytopenia generally correlate to the stage of the disease with anaemia being 
the most commonly encountered haematologic abnormality and a significant predictor of 
progression to AIDS or death.
[7, 8]
 
 
The role of HAART in improving bone marrow function in HIV-infected individuals remains 
an area of intense investigation. Prior work has indicated that the primitive hematopoietic 
progenitor, CFU-GEMM, is not infected by HIV per se,
[9]
 although the function of this cell in 
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terms of subsequent growth of committed progenitor cells is clearly abnormal.
[10]
 As a result 
of cell surface interactions with the HIV envelope protein, gp120/160, decreased colony 
growth of BFU-E, CFU-GM, CFU-G, and CFU-M has all been reported.
[10,11]
 Exposure of 
CD34+ progenitor cells to HIV may also promote apoptosis in these cells, with marked 
decrease in colony growth. In addition, the microenvironment of the marrow, which is 
necessary for normal blood cell growth and development, is also abnormal.  
 
Anemia is very common among HIV-infected individuals, occurring in approximately 30% 
of patients during the initial asymptomatic period of infection and in over 80% during the 
course of disease. The prevalence and correlates of anaemia have been studied in several 
large cohort studies.
[12]
 USDHHS
[8]
 and Gea-Banacloche
[13]
 separately reported 
improvements in haematocrit and haemoglobin values resulting in reduction in morbidity and 
mortality of HIV patients and 
[14]
 reported no improvement in haematocrit values of HAART 
treated HIV patients compared with HAART-naïve patients. HAART though effective in 
improving on haematocrit and decreasing the prevalence of anaemia could lead to a decrease 
in platelet counts. 
 
In addition to anaemia, patients with HIV infection may also have neutropenia, 
granulocytopenia and monocytopenia. Thus, abnormal Fc processing by macrophages has 
been described, while decreased opsonization and intracellular killing of bacterial or fungal 
organisms by granulocytes has also been reported.
[15] 
 
Cytopenia involving more than one haematopoietic linage impairment are common 
complications of HIV.Bone marrow dysfunction has been suggested as a possible mechanism 
of thios complication.
[16]
 Some antiretroviral drugs have also been documented to have 
cytopenic effect especially when use as monotherapy.
[17] 
Some of these complications as 
attributed to Nevirapine are eosinophilia and granulopenia. Those attributed to Zidovudine 
and Stavudine include neutropenia, anaemia and thrombocytopenia. 
 
Although haematological abnormalities are common manifestations of HIV infection and 
AIDS, and may have considerable impact on patients’ well-being, treatment and care, few 
studies on haematological parameters in HIV-infected persons comparing HAART have been 
undertaken in Nigeria. Such information for HIV-infected adults on HAART may help to 
inform treatment of HIV-infected individuals in this region. 
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HIV infected population are prone to liver disease.
[18]
 Initiation of HAART further worsens 
this due to the toxic effects of antiretroviral therapy. Some of these complications of HAART 
include hepatotoxicity, hyperlipidemia, hyperglycemia, hypolactatemia, lactic acidosis, 
lipodystrophy, hepatic steatosis.
[19,20]
 Other complications include neurological complications 
and organ related malignancies, bone and connective tissue disorders, cardiovascular, renal 
and hepatic diseases are some of the serious non-AIDS events which are responsible for 
morbidity and mortality in HAART era.
[21,22,23] 
 
Several HAART combinations are now being used in Nigeria hence it becomes imperative to 
study their effects on haematological parameters and compare the performance of each 
combination with regards to haematological parameters. 
 
2. METHOD 
Study design 
This study is a cross sectional study, participants were confirmed cases retro positive clients 
attending Heart to Heart Center, General Hospital Calabar. HIV status was confirmed using 
the HIV serial testing algorithm.
[24]
 All subjects satisfied the conditions of being non-
pregnant, with records of CD4 cell count and Haematological parameter assessment pre-
HAART commencement, commencement of HAART at least six months and maintaining a 
single HAART regimen which must also be the first ever used. In addition, candidates were 
not on any anti-tuberculosis therapy and must be on one of the ART combination of interest. 
The pre-HAART CD4 count, haematological parameter assay result and HAART regimen 
details were collected from the LAMIS data base of the facility.  Two hundred and thirty one 
(231) blood samples were collected from Retro positive clients that have been on the 
following HAART regimen for at least six months. Ethical approval to access baseline data 
of freely consenting client’s as they come for their periodic checkup was sort from the 
facility. 
 
Antiretroviral therapy combinations of used in this study 
 
 
 NAME OF HAART Components 
1 COMBIVIR(NVP) Zidovudine Lamivudine Nevirapine 
2 COMBIVIR(EFV) Zidovudine Lamivudine Efavirenz 
3 TRUVADA(NVP) Tenofovir Emtricitabine Nevirapine 
4 TRUVADA(EFV) Tenofovir Emtricitabine Efavirenz 
5 LANTEN(NVP) Tenofovir Lamivudine Nevirapine 
6 LANTEN(EFV) Tenofovir Lamivudine Efavirenz 
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Sample Collection 
2ml of venous blood was collected from each patient into a vacutainer containing EDTA, 
following standard phlebotomy procedure six month after HAART initiation. 
 
Data Collection 
The pre-HAART (baseline) of CD4 count, haematological parameter assay result and 
HAART regimen details were collected from the LAMIS data base of the Heart to Heart 
center. 
 
Sample analysis 
CD4 count was carried out by Flow Cytometric method using the automated PARTEC 
Cyflow machine (version 2.4), haematological parameters were analyzed using the SYSMEX 
KX-21 automated haemoanalyser machine.
[25] 
Data obtained were collected was analyzed with PASW (version 18) statistical package. 
 
Statistical analysis: One way ANOVA was carried out on data collected. 
 
3. RESULTS 
Amongst the clients sampled 68.8%(157) were placed on Combivir(NVP), 15.7%(37) on 
Combivir(EFV), 5.1%(12) on Truvada(NVP), 5.5%(13) on Truvada(EFV), 3.4%(8) on 
Lanten(NVP) and 3.0%(7) on Lanten(EFV).  
 
The mean values and standard errors of mean plot for CD4 count and other haematological 
parameters as presented in figure 1. 
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Figure 1. Shows CD4 count, WBC, Lymphocytes, Neutrophils, PCV, HGB, Platelet 
count, Eosinophils pre and 6months post commencement of HAARTS. 
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Table 1: Difference in mean values of Pre-HAART (baseline), six months Post-HAART 
treatment and P-value at 95% confidence limit. 
 
COMBIVIR 
(NVP) 
COMBIVIR 
(EFV) 
TRUVADA 
(NVP) 
TRUVADA 
(EFV) 
LANTE
N (NVP) 
LANTEN 
(EFV) 
P-VALVE 
(95%confidence 
limit) 
CD4 (cell mm-3) 154 205 172 206 262 230 0.478 
HAEMOGLOBIN 
(g/dl) 
-0.78 -0.73 2.35 1.48 1.11 1.27 0.01* 
PCV (%) -2.34 -2.19 7.05 7.02 3.36 3.12 0.001* 
WBC (10
3
µL
-1
) -1.19 -1.02 -0.37 -0.06 -1.14 -0.63 0.01* 
NEUTROPHIL 
(%) 
-1.51 -1.83 3.87 2.07 2.71 1.97 0.868 
LYMPHOCYTE 
(%) 
-4.26 -2.87 -1.45 -0.19 2.36 3.4 0.79 
PLATELET 
(10
3
µL
-1
) 
-49 -39 -53 -53 -47 -35 0.931 
EOSINOPHIL 
(%) 
-0.41 0.14 -2.65 0.14 -0.46 0.12 0.094 
 PVC=Packed Cell Volume. 
 WBC= White Blood Cell. 
 * = statistically significant 
 
4. DISCUSSION 
In this study, increases in CD4 cell count ranging from 154cellmm
-3 
to 262 cellmm
-3 
were 
recorded, indicating a promising life expectancy as the immune cells which are the major 
target of the virus appreciated in number. The variations in increases of CD4 counts between 
the groups was not statistically significant (p>0.05). This observation is supported by the 
report of Nacoulma et al.,
[26] 
who reported an immunological efficacy of 119 cellmm
-3 
at the 
end of the firstsix months of HAART. 
 
The mean values of packed cell volume and haemoglobin estimation decreased in clients on 
Combivir(NVP) and Combivir(EFV). Incidentally both drugs are zidovudine based drugs 
when compared with their various baseline values. Those on drugs devoid of zidovudine 
showed an appreciation (P<0.05) in the mean haemoglobin and packed cell volume values. 
This findings well agrees with the report of Mildvan et al.,
[27] 
who reported an association of 
anaemia, neutropenia and leucopenia with zidovudine based HAART. This is as a result of 
haematological toxicity caused by inhibition of haematological progenitor cells, resulting in 
myelosuppression.
[28]
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Ayer et al.,
[29]
 in their report compared HAART naïve clients and those basically on 
zidovudine based HAART regimen and proposed that the HAART naïve clients have a five 
times tendency of developing anaemia than those on zidovudine based HAART. Ippoliton 
and Puro
[30]
 demonstrated the reversibility of zidovudine induced haematological toxicity in 
experimental animals. A similar study in uninfected health workers by Owiredu et al.,
[31]
 
showed that the anaemia is reversible. 
 
The mean neutrophil count reduced in the groups treated with Combivir(NVP) and 
Combivir(EFV) i.e. zidovudine based drugs. In contrast, there was increased neutrophil count 
in the group given Truvada(NVP), Truvada(EFV), Lanten(NVP) and Lanten(EFV). The latter 
four are tenofovir based and the observed increases is supported by the findings of Owiredu 
et al.,
[31] 
who reported an increase in haemoglobin  and   Neutrophil count after a switch from 
HAART regimen containing zidovudine/lamivudine (combivir) to those containing tenofovir. 
There was however, no statistically significant difference (P>0.05) in the Neutrophil count 
obtained from various HAART combinations. 
 
A general trend of reduction (P>0.05) in platelet count throughout the various HAART 
combination groups was noted. This is indicative of the tendency of HAART to potentiate 
thrombocytopenia. Yakubu et al.,
[19]
 reported a little increase in platelet count in clients on 
zidovudine based HAART which include Combivir(NVP) and Combivir(EFV). Racial 
differences in the study population may explain the differences in the observations. There 
could also be a counter balancing struggle between the haemopoiesis depressing effect HIV 
of on the platelets and attempt of HAART to ameliorate those effects. 
 
USDHHS
[8]
 and Odunukwe et al.,
[19]
 in separate study  reported an association of eosinopenia 
with Nevirapin based HAART, this is in total agreement with our findings as it was observed 
that there were decreases (P>0.05) in the eosinophil count of subjects on Combivir(NVP), 
Truvada(NVP) and Lanten(NVP) which are all Nevirapin based. 
 
It was observed that zidovudine based HAART has many side effects on the haematological 
parameters but promotes life expectancy as evidenced by the increase in CD4+ counts. This 
underlines the importance of haematological monitoring of individuals placed on a 
zidovudine based HAART regimen. 
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In studying effects of HAART on haematological parameters, if the difference in handling 
HAART in non-infected experimental subject and infected subject will most likely present 
different scenario because HIV in itself has a great damaging effect on haematological 
parameters and HAART would have a lot of work to do to ameliorate these effects as against 
non-infected subjects which may have every condition been normal. 
 
5. CONCLUSION 
To a large extent, it was observed that zidovudine based HAART has many side effects on 
the haematological parameters. It however has a lot of advantages also in its promotion of life 
expectancy. It thus makes it very difficult to discard these drugs as it is also a fact that there is 
no one drug without side effects. Other drugs indeed may not have showed too many side 
effects on the haematological parameters as zidovudine as done but there are many 
physiological and chemical side effects some of which may be irreversible reported by other 
literatures. It however becomes very critical that proper haematological investigations and 
considerations be made before and during zidovudine based HAART therapy. 
 
Many recent studies have been done and are still on going on the use of some haematological 
investigations and parameters as a surrogate for some more complex and expensive 
investigations required for the monitoring of response of clients on HAART in rural areas. It 
however becomes pertinent to give some more considerations to likely variations that are 
likely to occur due to various HAART combinations. 
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